Advirna
Private Company
Funding information not available
Overview
Advirna is a private, early-stage biotech service provider specializing in oligonucleotide therapeutics. Unlike a traditional biopharma developing its own drug pipeline, Advirna operates as a nimble CRO, offering end-to-end services from target identification and oligonucleotide design to synthesis, screening, and custom assay development for external partners. Its business model is built on providing scientific expertise, iterative project design, and personalized support to accelerate the research programs of academic institutions and other biotech companies, positioning it as an enabler within the broader RNA therapeutics ecosystem. The company appears to be in an early-revenue stage, generating income through its service contracts.
Technology Platform
Integrated service platform for oligonucleotide therapeutic discovery, including design, synthesis, screening (siRNA/ASO), proprietary HYBRID-ON™ detection assay, and custom assay development.
Opportunities
Risk Factors
Competitive Landscape
Advirna competes in the niche of oligonucleotide-focused CRO services. Key competitors include large global CROs (e.g., Charles River, Labcorp) with RNA service divisions, specialized oligonucleotide synthesis/screening firms, and academic core facilities. Its differentiation lies in a full-stack, collaborative, and scientifically-deep service model tailored specifically to siRNA/ASO discovery.